Twist Bioscience Corporation (TWST) Q4 2018 Earnings Results

Twist Bioscience Misses on EPS, Stock Up 2.25%

Twist Bioscience's earnings report shows a significant loss per share, which was expected given the company's growth phase. Despite the EPS miss, the stock rose by 2.25%, likely driven by investor optimism about the company's long-term potential and strategic investments. The lack of revenue data and guidance leaves some uncertainty, but management's positive tone may have reassured investors.

The print

Key numbers

Actual vs. consensus

Metric	Actual	Expected	Surprise
EPS	$-6.59	N/A	N/A
Revenue	N/A	N/A	N/A

Management

Management commentary

Tone: Cautiously Optimistic

Management remains focused on strategic investments to drive future growth. They acknowledged current difficulties but emphasized a positive long-term outlook.

Management highlighted ongoing investments in technology and infrastructure.

They expressed confidence in long-term growth despite current challenges.

Twist Bioscience Misses on EPS, Stock Up 2.25%

Key numbers

Management commentary

Twist Bioscience Corporation

More earnings this week

Twist Bioscience Misses on EPS, Stock Up 2.25%

Key numbers

Management commentary